Skip to header Skip to main navigation Skip to main content Skip to footer
Home
Academic Citations from Palestine
Foregrounding the Research of Academics in Palestine

Main navigation

  • Home
  • Search
  • About

Determining the role of statins in Parkinson's disease risk reduction and disease modification: A comprehensive meta-analysis of 4 million participants' data

Blank
Al-Azhar University – Gaza
Mady A.; Nabil Y.; Daoud A.; Alnajjar A.Z.; Alsalloum T.; Marwan M.; Abdelmeseh M.; Elsayed M.; Krayim A.; Alaa M.; Masoud M.; Bushara N.; Faisal R.; Ahmed H.; Saad M.; Belabaci Z.; Barrett M.J.; Berman B.; Negida A.
Mady, Abdelrahman (59245541100); Nabil, Yehia (57560589200); Daoud, Asma (57195055384); Alnajjar, Asmaa Zakria (58648008200); Alsalloum, Taleb (58781741400); Marwan, Menna (57893971700); Abdelmeseh, Maickel (58781958200); Elsayed, Moaz (58781741300); Krayim, Abdulrahman (58782399500); Alaa, Mohamed (58219234800); Masoud, Mahmoud (59246381400); Bushara, Nagham (59209969800); Faisal, Roaa (57779229100); Ahmed, Hayat (59743219500); Saad, Mohamed (59244935100); Belabaci, Zineddine (59246381500); Barrett, Matthew J. (56486930700); Berman, Brian (36717257000); Negida, Ahmed (56845873000)
59245541100; 57560589200; 57195055384; 58648008200; 58781741400; 57893971700; 58781958200; 58781741300; 58782399500; 58219234800; 59246381400; 59209969800; 57779229100; 59743219500; 59244935100; 59246381500; 56486930700; 36717257000; 56845873000
2024
CNS Neuroscience and Therapeutics
Determining the role of statins in Parkinson's disease risk reduction and disease modification: A comprehensive meta-analysis of 4 million participants' data
30
8
John Wiley and Sons Inc
e14888
Medical research group of Egypt, Negida Academy, Arlington, MA, United States; Faculty of Medicine, Al-Azhar University, Cairo, Egypt; Faculty of Medicine, Zagazig University, Zagazig, Egypt; Medical research group of Algeria, Negida Academy, Arlington, MA, United States; Faculty of Medicine, Ferhat Abbas University, Setif, Algeria; Medical research group of Palestine, Negida Academy, Arlington, MA, United States; Faculty of Medicine, Al-Azhar University, Gaza, Palestine; Medical research group of Syria, Negida Academy, Arlington, MA, United States; Faculty of Medicine, University of Hama, Hama, Syrian Arab Republic; Faculty of Medicine, Port Said University, Port Said, Egypt; Faculty of Medicine, Alexandria University, Alexandria, Egypt; Faculty of Medicine, Cairo University, Cairo, Egypt; Faculty of Medicine, Minia University, Minia, Egypt; Faculty of Medicine, Al-Azhar University, New-Damietta, Egypt; Medical research group of Sudan, Negida Academy, Arlington, MA, United States; School of Medicine, Ahfad University for Women, Omdurman, Sudan; Faculty of Medicine, Azza University College for Women, Khartoum, Sudan; Faculty of Medicine, Ain Shams University, Cairo, Egypt; Faculty of Medicine, Djillali Liabes University, Sidi Bel Abbes, Algeria; Department of Neurology, Virginia Commonwealth University, Richmond, VA, United States
Mady A., Medical research group of Egypt, Negida Academy, Arlington, MA, United States, Faculty of Medicine, Al-Azhar University, Cairo, Egypt; Nabil Y., Medical research group of Egypt, Negida Academy, Arlington, MA, United States, Faculty of Medicine, Zagazig University, Zagazig, Egypt; Daoud A., Medical research group of Algeria, Negida Academy, Arlington, MA, United States, Faculty of Medicine, Ferhat Abbas University, Setif, Algeria; Alnajjar A.Z., Medical research group of Palestine, Negida Academy, Arlington, MA, United States, Faculty of Medicine, Al-Azhar University, Gaza, Palestine; Alsalloum T., Medical research group of Syria, Negida Academy, Arlington, MA, United States, Faculty of Medicine, University of Hama, Hama, Syrian Arab Republic; Marwan M., Medical research group of Egypt, Negida Academy, Arlington, MA, United States, Faculty of Medicine, Port Said University, Port Said, Egypt; Abdelmeseh M., Medical research group of Egypt, Negida Academy, Arlington, MA, United States, Faculty of Medicine, Alexandria University, Alexandria, Egypt; Elsayed M., Medical research group of Egypt, Negida Academy, Arlington, MA, United States, Faculty of Medicine, Cairo University, Cairo, Egypt; Krayim A., Medical research group of Egypt, Negida Academy, Arlington, MA, United States, Faculty of Medicine, Al-Azhar University, Cairo, Egypt; Alaa M., Medical research group of Egypt, Negida Academy, Arlington, MA, United States, Faculty of Medicine, Minia University, Minia, Egypt; Masoud M., Medical research group of Egypt, Negida Academy, Arlington, MA, United States, Faculty of Medicine, Al-Azhar University, New-Damietta, Egypt; Bushara N., Medical research group of Egypt, Negida Academy, Arlington, MA, United States, Faculty of Medicine, Zagazig University, Zagazig, Egypt; Faisal R., Medical research group of Sudan, Negida Academy, Arlington, MA, United States, School of Medicine, Ahfad University for Women, Omdurman, Sudan; Ahmed H., Medical research group of Sudan, Negida Academy, Arlington, MA, United States, Faculty of Medicine, Azza University College for Women, Khartoum, Sudan; Saad M., Medical research group of Egypt, Negida Academy, Arlington, MA, United States, Faculty of Medicine, Ain Shams University, Cairo, Egypt; Belabaci Z., Medical research group of Algeria, Negida Academy, Arlington, MA, United States, Faculty of Medicine, Djillali Liabes University, Sidi Bel Abbes, Algeria; Barrett M.J., Department of Neurology, Virginia Commonwealth University, Richmond, VA, United States; Berman B., Department of Neurology, Virginia Commonwealth University, Richmond, VA, United States; Negida A., Medical research group of Egypt, Negida Academy, Arlington, MA, United States, Department of Neurology, Virginia Commonwealth University, Richmond, VA, United States
A. Negida; VCU Parkinson's and Movement Disorders Center, Richmond, 1101 East Marshall Street, 23298-0599, United States; email: ahmed.said.negida@gmail.com
5
10.1111/cns.14888
disease risk; hydroxymethylglutaryl-coenzyme A reductase inhibitors; meta-analysis; Parkinson's disease; statins; symptom progression
Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Parkinson Disease; Risk Reduction Behavior; atorvastatin; fluvastatin; hydroxymethylglutaryl coenzyme A lyase; hydroxymethylglutaryl coenzyme A reductase inhibitor; lyase; nonsteroid antiinflammatory agent; pravastatin; rosuvastatin; simvastatin; hydroxymethylglutaryl coenzyme A reductase inhibitor; Article; blood brain barrier; body mass; bradykinesia; brain ischemia; cardiovascular disease; Cochrane Library; confounding bias; data extraction; depression; disease assessment; disease duration; disease modification; disease risk assessment; drug therapy; follow up; GRADE approach; high risk population; human; hypercholesterolemia; hypertension; incidence; medical procedures; Medline; meta analysis; nervous system inflammation; neuroprotection; Newcastle-Ottawa scale; Parkinson disease; physical activity; Preferred Reporting Items for Systematic Reviews and Meta-Analyses; publication bias; quality control; randomized controlled trial (topic); risk factor; risk reduction; Scopus; scoring system; sensitivity analysis; systematic review; Unified Parkinson Disease Rating Scale; Web of Science; epidemiology; prevention and control; risk reduction